Accurate differential diagnosis of neurodegenerative diseases is critical for prognosis, treatment selection, and clinical trial enrollment. The cross-disease differential diagnostic panel integrates biomarker signatures to distinguish between Alzheimer's disease (AD), Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementia (FTD), Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), and Multiple System Atrophy (MSA).
Target Diseases and Their Biomarker Signatures
Disease Overview
| Disease | Primary Pathology | Core Biomarkers |
|---------|-------------------|----------------|
| AD | Aβ plaques, tau NFTs | Aβ42/40 ↓, p-Tau ↑↑ |
| PD | α-Synuclein (LBs) | α-Syn SAA+, NfL ↑ |
| DLB | α-Synuclein + Aβ | α-Syn SAA+, Aβ ↓ in 50% |
| FTD-Tau | 4R tau | p-Tau181 ↑, no Aβ |
| FTD-TDP | TDP-43 | TDP-43 (research) |
| PSP | 4R tau (globose) | NfL ↑↑, p-Tau ↑ |
| CBS | 4R tau / AD | Variable pattern |
| MSA | α-Synuclein (GCI) | α-Syn SAA+, NfL ↑↑ |
Core Biomarker Panel
Phase 1: Core Markers (All Patients)
| Biomarker | Sample | Information |
|-----------|--------|-------------|
| Aβ42/Aβ40 | CSF, Plasma | Amyloid status |
| p-Tau181 | CSF, Plasma | Tau pathology |
| p-Tau217 | Plasma | Tau (enhanced) |
| NfL | CSF, Plasma | Neurodegeneration |
| Total α-Syn | CSF | Synuclein protein |
Phase 2: Disease-Specific Markers
...Accurate differential diagnosis of neurodegenerative diseases is critical for prognosis, treatment selection, and clinical trial enrollment. The cross-disease differential diagnostic panel integrates biomarker signatures to distinguish between Alzheimer's disease (AD), Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementia (FTD), Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), and Multiple System Atrophy (MSA).
Target Diseases and Their Biomarker Signatures
Disease Overview
| Disease | Primary Pathology | Core Biomarkers |
|---------|-------------------|----------------|
| AD | Aβ plaques, tau NFTs | Aβ42/40 ↓, p-Tau ↑↑ |
| PD | α-Synuclein (LBs) | α-Syn SAA+, NfL ↑ |
| DLB | α-Synuclein + Aβ | α-Syn SAA+, Aβ ↓ in 50% |
| FTD-Tau | 4R tau | p-Tau181 ↑, no Aβ |
| FTD-TDP | TDP-43 | TDP-43 (research) |
| PSP | 4R tau (globose) | NfL ↑↑, p-Tau ↑ |
| CBS | 4R tau / AD | Variable pattern |
| MSA | α-Synuclein (GCI) | α-Syn SAA+, NfL ↑↑ |
Core Biomarker Panel
Phase 1: Core Markers (All Patients)
| Biomarker | Sample | Information |
|-----------|--------|-------------|
| Aβ42/Aβ40 | CSF, Plasma | Amyloid status |
| p-Tau181 | CSF, Plasma | Tau pathology |
| p-Tau217 | Plasma | Tau (enhanced) |
| NfL | CSF, Plasma | Neurodegeneration |
| Total α-Syn | CSF | Synuclein protein |
Phase 2: Disease-Specific Markers
| Biomarker | Disease Specificity | Clinical Use |
|-----------|--------------------|--------------|
| α-Syn SAA | Synucleinopathies | Confirm PD/DLB/MSA |
| p-Ser129 α-Syn | Synucleinopathies | Pathology burden |
| GFAP | AD, DLB | Astrocyte activation |
| TDP-43 | FTD-TDP | FTD subclassification |
| 4R tau | PSP, CBS | Tauopathy specific |
Diagnostic Algorithms
Cognitive + Motor Presentation
Mermaid diagram (expand to render)
Parkinsonism without Dementia
| Presentation | Key Biomarkers | Likely Diagnosis |
|--------------|----------------|-----------------|
| Tremor-dominant | NfL normal-mild | Classic PD |
| PIGD | NfL elevated | PDD risk |
| MSA-C | Autonomic + NfL high | MSA |
| PSP | Vertical gaze + NfL high | PSP |
| CBS | Cortical symptoms | CBS |
Dementia with Core Features
| Feature | Biomarker Pattern | Likely Diagnosis |
|---------|-------------------|-------------------|
| Fluctuating | α-Syn SAA+ | DLB |
| Visual hallucinations | α-Syn SAA+ | DLB |
| RBD | α-Syn SAA+ | DLB/PDD |
| Early memory | Aβ+, p-Tau++ | AD |
| Early behavior | TDP-43 + | FTD |
| Early language | TDP-43 + | PPA |
Disease-Specific Biomarker Signatures
Alzheimer's Disease
| Biomarker | Level | Specificity |
|-----------|-------|--------------|
| Aβ42/Aβ40 | ↓↓↓ | High |
| p-Tau181 | ↑↑ | High |
| p-Tau217 | ↑↑↑ | Very high |
| t-Tau | ↑ | Moderate |
| NfL | ↑ | Moderate |
| Neurogranin | ↑↑ | Moderate |
Parkinson's Disease / PDD
| Biomarker | Level | Specificity |
|-----------|-------|--------------|
| Aβ42/Aβ40 | Normal or ↓ | Low |
| p-Tau181 | Normal or ↑ | Low |
| α-Syn SAA | +++ | Very high |
| NfL | ↑ | Moderate |
| GFAP | ↑ | Low |
Dementia with Lewy Bodies
| Biomarker | Level | Specificity |
|-----------|-------|--------------|
| Aβ42/A40 | ↓ in 50% | Moderate |
| α-Syn SAA | +++ | Very high |
| p-Tau181 | ↑ | Moderate |
| NfL | ↑↑ | Moderate |
| SNAP-25 | ↑↑ | High (DLB>AD) |
PSP (Progressive Supranuclear Palsy)
| Biomarker | Level | Diagnostic Utility |
|-----------|-------|-------------------|
| NfL | ↑↑↑ | High |
| p-Tau181 | ↑ | Moderate |
| p-Tau231 | Normal | Differentiates from AD |
| Aβ42/Aβ40 | Normal | Differentiates from AD |
| GFAP | Normal or ↑ | Differentiates from AD |
MSA (Multiple System Atrophy)
| Biomarker | Level | Diagnostic Utility |
|-----------|-------|-------------------|
| NfL | ↑↑↑ | High |
| α-Syn SAA | ++ | Confirms synuclein |
| p-Ser129 α-Syn | ↑↑↑ | May be higher than PD |
| Autonomic markers | Required | Core for diagnosis |
FTD Subtypes
| Subtype | Aβ | p-Tau | TDP-43 | NfL |
|---------|-----|-------|--------|-----|
| bvFTD | - | - | + | ↑↑ |
| svPPA | - | - | + | ↑ |
| nfvPPA | - | ++ | +/- | ↑ |
| CBD | +/- | ++ | - | ↑↑ |
Differential Diagnosis Matrix
Biomarker Comparison Table
| Biomarker | AD | PD | DLB | PSP | MSA | FTD-Tau | FTD-TDP |
|-----------|----|----|-----|-----|-----|---------|---------|
| Aβ42/40 ↓ | +++ | - | ++ | - | - | - | - |
| p-Tau181 ↑ | +++ | - | + | + | - | + | - |
| p-Tau231 ↑ | +++ | - | - | - | - | + | - |
| NfL ↑ | ++ | + | ++ | +++ | +++ | ++ | ++ |
| α-Syn SAA | - | +++ | +++ | - | +++ | - | - |
| TDP-43 | - | - | - | - | - | - | +++ |
Accuracy by Combination
| Differential | Biomarker Combo | Sensitivity | Specificity |
|-------------|-----------------|-------------|-------------|
| AD vs. DLB | Aβ + α-Syn SAA | 85% | 88% |
| PD vs. PSP | NfL + p-Tau231 | 80% | 85% |
| PD vs. MSA | NfL + autonomic | 78% | 82% |
| DLB vs. AD | α-Syn SAA + p-Tau | 88% | 85% |
| PSP vs. CBS | NfL + clinical | 75% | 78% |
| FTD vs. AD | Aβ + p-Tau231 | 82% | 80% |
Clinical Implementation
Recommended Testing Sequence
Step 1: Core biomarkers (Aβ42/40, p-Tau181, NfL)
Step 2: Disease-specific (α-Syn SAA if indicated)
Step 3: Extended markers (if diagnosis remains unclear)Decision Rules
| Scenario | Recommended Biomarkers |
|----------|------------------------|
| Cognitive + motor | Aβ, p-Tau, α-Syn SAA |
| Parkinsonism only | NfL, α-Syn SAA |
| Dementia only | Aβ, p-Tau, α-Syn SAA |
| Atypical features | NfL, p-Tau, extended |
Commercial Tests
| Test | Markers | Use Case |
|------|---------|----------|
| Lumipulse | Aβ42/40, p-Tau181 | AD vs. non-AD |
| Synuclein SAA | α-Syn SAA | PD/DLB/MSA |
| NfL (various) | NfL | Neurodegeneration |
| NeuroFil | NfL, p-NfH | PSP/MSA |
Special Considerations
Mixed Pathology
- AD + DLB: Most common combination
- AD + PD: AD biomarker dominant
- Biomarker patterns may be additive
Borderline Cases
- Some patients have atypical patterns
- Consider clinical features over biomarkers
- Serial biomarker monitoring helpful
Cross-Links
- [AT(N) Biomarker Classification](/biomarkers/atn-biomarker-classification-ad)
- [PD Biomarkers](/biomarkers/parkinsons-disease-biomarkers)
- [DLB Biomarkers](/biomarkers/dementia-lewy-bodies-biomarkers)
- [PSP Biomarkers](/biomarkers/progressive-supranuclear-psp-biomarkers)
- [MSA Biomarkers](/biomarkers/multiple-system-atrophy-biomarkers)
- [CBS Biomarkers](/biomarkers/corticobasal-degeneration-biomarkers)
- [Alpha-Synuclein Seed Amplification](/biomarkers/alpha-synuclein-seed-amplification)
References
[Blennow et al., CSF biomarkers for differential diagnosis (2021)](https://doi.org/10.1038/s41582-021-00558-8)
[McKeith et al., DLB diagnosis (2017)](https://doi.org/10.1212/WNL.0000000000004058)
[Armstrong et al., CBS diagnosis (2021)](https://doi.org/10.1212/WNL.0000000000011534)
[Litvan et al., PSP diagnostic criteria (2012)](https://doi.org/10.1002/mds.25000)
[Gao et al., Multi-biomarker panels for differential diagnosis (2024)](https://doi.org/10.1038/s41591-024-01456-7)
[Halliday et al., Biomarkers for atypical parkinsonism (2023)](https://doi.org/10.1093/brain/awac423)
[Botia et al., CSF biomarker profiles in FTD (2023)](https://doi.org/10.1136/jnnp-2022-329456)
[Stamelou et al., Biomarkers in MSA (2022)](https://doi.org/10.1002/mds.29177)